The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

DeVaney was named interim president of Caremark's PBM business in December 2024. CVS Health has named Ed DeVaney president of the company’s Caremark pharmacy benefit management business. Named interim ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

CVS Health has named Ed DeVaney as president of its pharmacy benefit manager, CVS Caremark. | DeVaney has served as interim ...

CVS Health has eliminated more than 1,000 jobs based at or reporting to its offices in Hartford, which include the ...

Q4 2024 Earnings Call Transcript February 12, 2025 CVS Health Corporation beats earnings expectations. Reported EPS is $1.19, ...

We recently published a list of These 10 Stocks Led Rally on Wednesday. In this article, we are going to take a look at where ...

CVS Health downgraded to Hold due to political risks, declining cash flow, and industry battles despite strong Q4 sales and a ...

Some analysts are more optimistic about CVS’ ability to navigate higher-than-expected medical costs in its insurance unit ...

CVS Health Corp issued an optimistic guidance for 2025 stemming from the expected recovery in its insurance business — Aetna's turnaround.

CVS CEO David Joyner just finished his first full quarter at the helm. He spoke with Yahoo Finance about the conservative ...